Brief: Aravive Announces Initiation Of Investigator-Sponsored Phase 1/2 Study Of AVB-500 In Combination With Avelumab

Aravive

24/03/2020 12:25

March 24 (Reuters) - Aravive Inc  ARAV.O :
    * ARAVIVE ANNOUNCES INITIATION OF INVESTIGATOR-SPONSORED
PHASE 1/2
STUDY OF AVB-500 IN COMBINATION WITH AVELUMAB IN PATIENTS WITH
ADVANCED UROTHELIAL CARCINOMA (COAXIN)
    * ARAVIVE INC - PATIENT ENROLLMENT AND CONTINUATION ON STUDY
MAY
BE IMPACTED BY COVID-19

Source text for Eikon:  ID:nGNX94mqrz 
Further company coverage:  ARAV.O 

 ((Reuters.Briefs@thomsonreuters.com;))